Abstract
Pharmacologic thrombolysis has substantially improved the outcome of patients with acute myocardial infarction. Whether additional significant reductions in morbidity and mortality can be achieved by attenuating recurrent thrombosis or reperfusion injury remains to be demonstrated in clinical trials. Recent data suggest that administration of fibrinolytic agents in patients with acute myocardial infarction may potentiate procoagulant and proinflammatory activity. The results of experimental studies suggest that there is the potential for further improvements in the success of coronary thrombolysis by inhibiting plasmin-mediated mechanisms for activation of the coagulation and complement systems.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
